Alpha Tau Medical Ltd

RTTNews highlights five biotech and medical device stocks that generated returns of 86% to 327% since being featured on its website. Arrowhead Pharmaceuticals surged 222% to a 52-week high of $95.49 following FDA approval of its lead drug Redemplo and positive clinical data. Compass Pathways climbed 327% to a 3.5-year high of $15.40 after reporting positive Phase 3 results for its psilocybin therapy COMP360 in treatment-resistant depression. CG Oncology rose 148% to an all-time high of $77.00 on the back of encouraging data for its bladder cancer candidate Cretostimogene. Alpha Tau Medical gained 182% to a 52-week high of $14.11 driven by regulatory progress and promising clinical results for its Alpha DaRT cancer therapy. Electromed advanced 86% to a 52-week high of $47.40 supported by strong quarterly revenue and profit growth.

Alpha Tau Medical announced the successful treatment of the first patient in its ADMIRE study, a clinical trial evaluating Alpha DaRT for immunocompromised patients with recurrent cutaneous squamous cell carcinoma. The procedure was performed at Banner MD Anderson Cancer Center in Gilbert, Arizona, by Dr. Michael Samuels and Dr. Thomas Shellenberger. Immunocompromised patients, including organ transplant recipients who face a 65- to 100-fold higher incidence of cSCC, often have limited treatment options because checkpoint inhibitor immunotherapy can risk organ rejection and repeated surgeries or radiation become less feasible. The ADMIRE study, which plans to enroll up to 28 patients at up to 8 U.S. sites, is designed to assess whether the localized alpha-radiation therapy can offer a meaningful alternative for this historically excluded population. Alpha Tau's CEO Uzi Sofer noted that the trial originated from physician requests after the company's ReSTART pivotal trial for recurrent cSCC, which recently completed enrollment and also involved the Banner MD Anderson team.